# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-24-000056
Filing Date
2024-08-01
Accepted
2024-08-01 16:54:04
Documents
7
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | q22024form6-k.htm | 6-K | 22463
2 | EX-99.1 2024 SECOND QUARTER INTERIM FINANCIAL STATEMENTS | ex991-interimfsjune302024.htm | EX-99.1 | 392680
3 | EX-99.2 2024 SECOND QUARTER MD&A | ex992-q22024mda.htm | EX-99.2 | 243665
4 | EX-99.3 Q2 2024 CERTIFICATION CEO | ex993-q22024certificationx.htm | EX-99.3 | 14355
5 | EX-99.4 Q2 2024 CERTIFICATION CFO | ex994-q22024certificationx.htm | EX-99.4 | 14280
6 |  | oncolyticslogotaglinebluea.jpg | GRAPHIC | 355294
7 |  | oncolyticspipeline.jpg | GRAPHIC | 654350
| Complete submission text file | 0001129928-24-000056.txt |  | 2028788

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 241167569
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)